Bronchitis
Conditions
Brief summary
This is a multicenter, randomized, open Label,add-on study.
Detailed description
This is an add-on study of efficacy and safety of intravenous injection of Xiyanping injection in subjects with pediatric bronchitis. The purpose to determine the efficacy and safety of conventional treatment combined with or without Xiyanping injection in the treatment of pediatric bronchitis and to further evaluate the clinical value of Xiyanping injection in shortening the course of pediatric bronchitis The study will enroll 240 Pediatric bronchitis volunteers, who will be randomized into 2 groups (1:1 ratio): volunteers from the first group will receive Routine treatment for pediatric bronchitis and Xiyanping injection; volunteers from the second group will receive Routine treatment for pediatric bronchitis. Xiyanping injection will be administration as intravenous injection of 0.2-0.4mL/kg/day once daily for 5 days concomitantly with Routine treatment for pediatric bronchitis
Interventions
standard treatment， such as antiasthmatic,expectorant,antipyretic
DRUGStandard treatment+Xiyanping injection
standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
Sponsors
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 3 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of pediatric bronchitis with hospital treatment needed * Males and female subjects * Age between 1 and 3 years old * With fever, cough, gasp and expectoration symptoms * Have wheeze and/ or mid-fine rales on one's lungs * White blood cell count \< 12 x 109 / L, categorized priority to leukocyte * C-reactive protein≤8mg/L or normal Super C- reactive protein * Had experienced ≤48 h course before enrollment * Previous Wheezing episodes≤2 * Written informed consent
Exclusion criteria
* Participants with severe clinical symptoms, meet any of the following： * SaO2≤0.92;（2）Shock or disturbance of consciousness;（3） Significantly speed up breathing , rapid pulse accompany with severe respiratory distress; or（4）Repeated occurrence of apnea or slow and irregular respiration; * Acute infectious disease such as measles, pertussis and influenza * Participants with bronchial asthma, bronchopneumonia and other respiratory diseases * Chronic lung diseases * Participants with complicated pyopneumothorax, airway obstruction, toxic encephalopathy, cardiac failure or respiratory failure * Participants with complicated severe underlying myocardial, liver, kidney, digestive and hematopoietic system diseases * Severe malnutrition and history of immune deficiency which may seriously affect the self-limiting process of the course * Participants with epilepsy and other disturbances of central nervous system * Participants with congenital diseases and psychosis * use of any other antiviral drugs within the 2 weeks before enrollment * use of systemic hormone within the 2 weeks before enrollment * Participants had a history of allergic constitution and drug allergy; Allergenic to XiYanPing injection and Andrographolide * Participants participated in other clinical research in the last three months * Any condition which would make the subject, in the opinion of the investigator or designee, not suitable for the study for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to total score of the clinical symptoms/signs decreased more than 70% from baseline | up to 30 days after the last Administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to defervescence | up to 30 days after the last Administration | — |
| Day(s) of Hospital Stay | up to 30 days after the last Administration | — |
| Signs and Symptoms Score from baseline | up to 30 days after the last Administration | — |
| Antibiotic consumption | up to 30 days after the last Administration | check and record the usage of antibiotic,including durg Utilization Rate and the duration of usage |
| Usage of Inhaled corticosteroids | up to 30 days after the last Administration | check and record the usage of Inhaled corticosteroids,including durg Utilization Rate and the duration of usage |
| The total efficiency rate | Day 3 and Day 5 | — |
| Sputum status | up to 30 days after the last Administration | record the incidence of expectoration and the day of expectoration disappear |
| Expenditure of therapeutic drug | up to 30 days after the last Administration | — |
| The total expenditure of treatment | up to 30 days after the last Administration | Expenditure of treatment include the cost of durg, hospitalization,examination |
| incidence of adverse events | up to 30 days after the last Administration | — |
| Incidence of complication | up to 30 days after the last Administration | record the incidence of new complication after treatment. |
Countries
China
Contacts
Primary ContactChen Xiao
Outcome results
None listed